← Leaderboards
Margaret Kenny Offermann
Oncospherix, Inc.
$2,449,774
Attributed
$2,449,774
Total exposure
2
Grants
2
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $1M · FY2020–24$2M$1.5M$1M$500K$0
'20
'21
'22
'23
'24
Funding mix
By agency
NIH$2,449,774 · 2
By mechanism
R44$2,050,000 · 1
R43$399,774 · 1
Top collaborators
No co-investigators on record.
Others in their field
Other Emerging Leaders on “Malignant Neoplasms”
- Leonard Freedman · Leidos Biomedical Research, Inc.$527,106,485
- Ethan Dmitrovsky · Leidos Biomedical Research, Inc.$357,875,933
- Lynn Briscoe · Leidos Biomedical Research, Inc.$186,892,879
- Leonard Freedmand · Leidos Biomedical Research, Inc.$108,968,336
- Beverly Hayes · Leidos Biomedical Research, Inc.$98,336,166
- Martha Hering · Westat, Inc.$57,098,843
Research focus
Malignant NeoplasmsOperative Surgical ProceduresHigh RiskMalignant Neoplasm Of EyeMouse ModelNeoplastic CellDoseFormulationHypoxia Inducible Factor 1In VivoMetastatic Neoplasm To The LiverBhlh-Pas Factor HlfNeoplasm MetastasisClinical TrialsAdultClinical ResearchCancer CellEfficacy StudyHypoxia Inducible FactorCell LineCellsImplantBehavioralOral
Grant awards (3)
Arylsulfonamides for the Treatment of Primary and Metastatic Uveal Melanoma$1,025,001
R44 · FY2024 · CA · contact PI
Arylsulfonamides for the Treatment of Primary and Metastatic Uveal Melanoma$1,024,999
R44 · FY2023 · CA · contact PI
Arylsulfonamides for the Treatment of Primary and Metastatic Uveal Melanoma$399,774
R43 · FY2020 · CA · contact PI